EMAIL THIS PAGE TO A FRIEND

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.


PMID 25445023

Abstract

Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P < .0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C104
(±)-CPP, solid
C8H17N2O5P
C2163000
Ciclosporin, European Pharmacopoeia (EP) Reference Standard
C62H111N11O12
Y0000361
Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard
C62H111N11O12
F4679
FK-506 monohydrate, ≥98% (HPLC)
C44H69NO12 · H2O
M1000000
Methotrexate, European Pharmacopoeia (EP) Reference Standard
C20H22N8O5
M7824
Methotrexate, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, meets EP, USP testing specifications
C20H22N8O5
PHR1396
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
C20H22N8O5
M4010
Methotrexate, meets EP, USP testing specifications
C20H22N8O5 · xH2O
M9929
Methotrexate, meets USP testing specifications
C20H22N8O5 · xH2O
Y0000602
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
C20H22N8O5
Y0001668
Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard
C20H22N8O5
SML0284
Mycophenolate mofetil, ≥98% (HPLC)
C23H31NO7
1448956
Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard
C23H31NO7
Y0000489
Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
C23H31NO7
PHR1451
Mycophenolate Mofetil, Pharmaceutical Secondary Standard; Certified Reference Material
C23H31NO7
Y0000519
Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard
C23H31NO7
1642802
Tacrolimus, United States Pharmacopeia (USP) Reference Standard
C44H69NO12 · H2O